Hypertension Clinical Trials

Showing 2881-2900 of 3,518 trials

Efficacy of Changing to TRAVATAN® From Prior Therapy

NCT01493427

The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.

Open-Angle GlaucomaOcular Hypertension

Alcon Research202 participantsStarted Dec 2011

COMPLETEDNA

Care Transitions for Complex Patient - Cycle 1 and Cycle 2

NCT01039324

The purpose of this study is to improve patient care and safety while decreasing ED visit rates by sending specific information about care transitions related to hospital admission and discharge and emergency department and specialty care visits to primary care practices, care managers and patients with the use of health information technology (HIT) shared across a community-based network of providers. Cycle 1 focuses on the impact of notices about ED encounters and hospitalizations derived from billing data that are sent to care managers for all 47,000 patients in the Northern Piedmont Community Care Network (NPCCN). Cycle 2 explores the impact of letters sent to patients, and care event reports sent to a patient's medical home in addition to notices sent to care managers about ED encounters, hospitalization and specialty care based on ADT (Admission Discharge Transfer) and billing data on 4,600 patients with complex health needs.

AsthmaCoronary Artery DiseaseDiabetes+2 more

Duke University8,422 participantsStarted Dec 2009

Durham, North Carolina, United States

TERMINATEDPhase 3

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00879229

Ambrisentan is an endothelin receptor antagonist used for the treatment of pulmonary hypertension (PH). Based on research suggesting a role for endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and the poor prognosis for patients with IPF who are also diagnosed with PH, this study was designed to evaluate the effectiveness and safety of ambrisentan in that patient population.

Idiopathic Pulmonary FibrosisPulmonary Hypertension

Gilead Sciences40 participantsStarted Jul 2009

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Davis, California, United States +82 more locations

Efficacy of Changing to TRAVATAN® From Prior Therapy

Care Transitions for Complex Patient - Cycle 1 and Cycle 2

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Related Searches

24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients

Observational Cohort Study of Sodium, Weight and Cardiovascular Disease

Effect of Blood Donation on Blood Pressure, Iron Metabolism, Oxidative Stress

Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

A Cross-sectional Study on Intradialytic Hypertension at Four Haemodialysis Units in the Western Cape

Clinical Validation of the Tiba Medical Ambulo 2400 ABPM According to the ISO 80601-2-30 Standard in Adults, Adolescents, and Children

Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)

Finding Early Predictors of Myocardial Dysfunction

A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

Flavanol-Rich Cocoa and Cerebral Blood Flow

Addition of Homeopathy in Patients With Resistant Arterial Hypertension

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Genes of Hypertension in African Americans

Blood Pressure Telemonitoring and Goal Blood Pressure in Diabetes

Amiloride for Resistant Hypertension

Effect of Mat Pilates Training on Blood Pressure of Hypertensive Individuals